TomoTherapy Names Rafael Vaello Vice President of Global Sales
Former Philips Healthcare executive brings proven sales experience
in oncology, imaging industries
MADISON, Wis. (Business Wire EON/PRWEB ) November 24, 2008 --
TomoTherapy
Incorporated (NASDAQ: TOMO), producer of the Hi·Art®
treatment system for advanced radiation therapy, today announced that
Rafael (Ralph) Vaello will join the company as vice president of global
sales, effective December 1, 2008. Mr. Vaello, who will report to
TomoTherapy CEO Fred Robertson, M.D., has spent the previous seven years
leading the sales and field marketing group for Philips
Healthcare’s Oncology Imaging division.
“Ralph is an experienced, results-oriented sales leader. He has
demonstrated repeated success at developing world-class sales
organizations that meet or exceed their performance goals,” said Dr.
Robertson. “We are confident that Ralph’s deep industry experience and
strong management style, combined with our technology’s recognized edge
in the treatment of cancer patients, will accelerate our market
penetration.”
Mr. Vaello brings more than 15 years of sales expertise in the oncology
and imaging industries to TomoTherapy, where he will be responsible for
enhancing sales performance and expanding the company’s global market
presence.
Prior to joining TomoTherapy, Mr. Vaello served as vice president, sales
and field marketing, for Philips Healthcare’s Oncology Imaging division,
where he exceeded aggressive budget plans in orders, sales and margin
attainment. Mr. Vaello was previously director, global sales manager,
for Marconi Medical Systems’ Oncology division. Prior to that, he held
various imaging and oncology sales positions for Picker International.
“TomoTherapy offers a revolutionary, efficient and versatile tool in the
arsenal against cancer. The success in this battle depends on innovative
technology, like the Hi·Art system, that enables aggressive
treatment options and individualized patient care,” said Mr. Vaello.
“I’m very excited to join the company at such a promising time in the
field of cancer treatment.”
Shawn Guse, who held the role of interim vice president of global sales
since August 25, 2008, will take on other executive responsibilities
within the organization, including continuing as the CEO of
TomoTherapy's proton therapy development subsidiary, Compact Particle
Acceleration Corporation.
“Shawn has stepped in and provided valuable leadership in a critical
role during his transition," said Dr. Robertson. “We appreciate Shawn’s
versatile talents and excellent leadership skills."
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the
TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy
system for the treatment of a wide variety of cancers. The Hi·Art treatment
system combines integrated CT imaging with conformal radiation therapy
to deliver sophisticated radiation treatments with speed and precision
while reducing radiation exposure to surrounding healthy tissue. The
company’s stock is traded on the NASDAQ Global Select Market under the
symbol TOMO. To learn more about TomoTherapy, please visit
TomoTherapy.com.
©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the
TomoTherapy logo and Hi·Art are among trademarks, service marks or
registered trademarks of TomoTherapy Incorporated.
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1Qcm9mLUluc2UtSW5zZS1Mb3ZlLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.